Two receptors. Stronger signal.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class. It was designed as a single molecule that activates both the GLP-1 receptor (shared with semaglutide) and the GIP (glucose-dependent insulinotropic polypeptide) receptor.
GIP is an incretin hormone produced in the small intestine. It enhances insulin secretion after meals, reduces glucagon levels, and appears to have direct effects on fat tissue metabolism. When you activate GIP alongside GLP-1, the downstream metabolic effects are additive — more robust insulin response, better glucose control, and enhanced fat metabolism beyond what GLP-1 alone produces.
The clinical trial data is notable. Tirzepatide demonstrated greater mean weight reduction than semaglutide at comparable doses in the SURMOUNT and SURPASS trial programs. It also showed improvements in A1C, triglycerides, and blood pressure that compare favorably to existing treatments.
The stronger starting point for some patients.
Tirzepatide is appropriate for patients who are starting a GLP-1 class medication and want the dual-receptor benefit from the beginning, or for patients who have used semaglutide and plateaued or experienced insufficient response.
For patients with significant insulin resistance, elevated triglycerides, or more substantial weight management goals, the additional GIP mechanism may provide meaningful advantages over GLP-1 monotherapy.
- Greater weight reduction than GLP-1 alone
- Improved A1C and glycemic control
- Better cardiometabolic markers
- Appetite and satiety regulation
- Dual incretin hormone pathway activation
Titrated gradually. Monitored throughout.
The titration approach mirrors semaglutide — starting at the lowest dose and escalating every 4 weeks based on tolerance. The GI side effect profile is similar; starting slow and following dietary guidance during the titration phase makes the difference between a smooth adjustment and a miserable first month.
| Phase | Dose | Duration |
|---|---|---|
| Starting dose | 2.5mg weekly | 4 weeks |
| Step 2 | 5mg weekly | 4+ weeks |
| Step 3 | 7.5–10mg weekly | 4+ weeks |
| Maintenance | 10–15mg weekly | Per response |
What you should know
Side effects are similar to semaglutide: nausea, constipation, decreased appetite, and possible vomiting during titration. The same management strategies apply — slow titration, smaller meals, adequate hydration, and patience with the adjustment period.
The same contraindications apply: personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, or known hypersensitivity. We review your history carefully before prescribing.
Common questions about Tirzepatide
In clinical trials, tirzepatide has shown greater mean weight reduction and comparable or better glycemic control. That doesn't mean it's the right choice for everyone — individual response varies, GI tolerability differs between patients, and cost may be a factor. We help you make the decision based on your specific situation.
Yes, and this is a common transition. The switch requires careful dose selection to account for the difference in potency between the two molecules. We manage this transition with appropriate overlap and monitoring.
Tirzepatide is FDA approved under the brand name Mounjaro (for type 2 diabetes) and Zepbound (for obesity). What we prescribe is compounded tirzepatide from a licensed 503B pharmacy, which is standard practice for medically supervised weight management.
We review your labs, goals, and health history before recommending any protocol. Available in-person in St. Louis or via secure telehealth.
📅 Request a Consultation →